We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.25 | -1.49% | 16.50 | 16.00 | 17.00 | 16.75 | 16.50 | 16.75 | 169,683 | 14:04:40 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 5.81 | 15.05M |
Date | Subject | Author | Discuss |
---|---|---|---|
25/4/2017 09:10 | Again no mention of numbers | branboyd1 | |
25/4/2017 09:08 | Cant see decent share price appreciation in the short term. | monkeywench1 | |
25/4/2017 09:08 | I managed to add 6,000. Total reflex as I was not expecting this news. | bobdown2 | |
25/4/2017 09:08 | Wow that certainty wasn't expected before launch. Excellent. | john henry | |
25/4/2017 09:07 | Parob, re your above post (22602). This is NOT adding an ingredient, it's being sold as a stand alone capsule. Best wishes - Mike | spike_1 | |
25/4/2017 09:06 | Costs will be tiny Deep, Sacco can manufacture these microbes for peanuts, very high margin business | trotterstrading | |
25/4/2017 09:06 | I can think of far worse territories to record FIRST commercial sales!Here's to a Blue day - the timing of the HLH deal announcement is intriguing..... | tightfist | |
25/4/2017 09:05 | Adding ingredients to already existing products... this was always part of the strategy and this is the first time we're seeing it. Plenty more to come. This is just the start! | parob | |
25/4/2017 09:04 | no wonder I can't buy online | nicktopten | |
25/4/2017 09:03 | No mention of what 100,000 units cost but great backing from a major supplier. Surely an operating profit isn't too far away - a question for tonight! | deeppockets | |
25/4/2017 09:03 | I'm pleased with the detailed update, looking very good as far as I'm concerned. | joyjoy13 | |
25/4/2017 09:02 | LP-LDL sales AHEAD of Vitafood expo launch. Nice! | elrico | |
25/4/2017 09:02 | Excellent news, sales in Germany. How many others will follow? | rafboy | |
25/4/2017 09:00 | Excellent news. 3rd revenue stream confirmed. Wouldn't surprise me if Sacco are already manufacturing for HLH. Watch as the floodgates now open up further deals with other corporates. They'll be scrambling for some of the action. What was it SOH said in a recent interview about sheep? | parob | |
25/4/2017 08:59 | Very significant and major milestone, looking forward to SoH's preso today | trotterstrading | |
25/4/2017 08:58 | LDL sales will be like a domino effect.. it's going to be very successful IMHO | trotterstrading | |
25/4/2017 08:56 | OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has agreed to supply 100,000 units of LP(LDL) (R) to HLH BioPharma Vertriebs GmbH ("HLH"). | parob | |
25/4/2017 08:56 | Someuwin,Probably because of the speculative nature of RNS and other management comments, very difficult to place value without revenues. | talkingtrade | |
25/4/2017 08:54 | No surprise that finnCap today put out another pointless update. Reiterating their meaningless 'Corporate' rating and giving no price target. | someuwin | |
25/4/2017 08:54 | What is the opportunity cost of holding these. | monkeywench1 | |
25/4/2017 08:54 | RNS NR 2!!!! | trotterstrading | |
25/4/2017 08:51 | scotty, I never use graphs as an aid to buy or not I just commented that I have seen better ones Looks a bit like Mount Everest at the moment | judijudi | |
25/4/2017 08:46 | News imminent on PCGE...Doc Holiday just posted on twitter... I have been giving the company respective space to do a deal, I anticipate this will be material and come soon enough buddy | smart solution |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions